로딩 중…
지수 로딩 중…
인트론바이오
048530· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,790+0.00%
2026-11-02
Financials
Valuation Metrics
인트론바이오's Market Cap is ₩860B. At end of 2025 it was ₩1004B. Ranked #1312 of 2,410 in KR market (top 54%), #722 of 1,631 on KOSDAQ (top 44%), #145 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 86.03B KRW | KR#1,312/2,410 Sec#145/231 |
| Revenue | 7.25B KRW | KR#2,303/2,410 Sec#183/231 |
| Net Income | -10.34B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 68.37B KRW | KR#2,024/2,410 Sec#169/231 |
| Net Assets | 62.17B KRW | KR#1,765/2,410 Sec#149/231 |
| Employees | 70 | KR#1,869/2,410 Sec#161/231 |
| Value | ||
| P/B | 1.39x | KR#1,777/2,410 Sec#124/231 |
| P/S | 11.90x | KR#2,293/2,410 Sec#170/231 |
| Profitability | ||
| ROE | -16.62% | KR#2,049/2,410 Sec#159/231 |
| ROA | -15.12% | KR#2,187/2,410 Sec#167/231 |
| Op. Margin | -109.18% | KR#2,297/2,410 Sec#177/231 |
| Revenue Growth | 40.90% | KR#273/2,410 Sec#32/231 |
| Financial Health | ||
| Debt Ratio | 9.97% | KR#142/2,410 Sec#30/231 |
| Total Debt | 4.80B KRW | KR#1,793/2,410 Sec#172/231 |
| Cash | 26.30B KRW | KR#1,085/2,410 Sec#74/231 |
| Current Ratio | 9.56x | KR#105/2,410 Sec#24/231 |
| Dividend | ||
| Div. Yield | 7.49% | KR#116/2,410 Sec#1/231 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -15.96% | KR#1,063/2,410 Sec#73/231 |
| 1M Return | -0.53% | KR#430/2,410 Sec#44/231 |
| From 52W High | -60.20% | KR#1,644/2,410 Sec#139/231 |
| 1Y MDD | -64.96% | KR#1,710/2,410 Sec#144/231 |
| Trading | ||
| Volume | 70,826 shares | KR#623/2,410 Sec#66/231 |
| Trading Value | 195.1M KRW | KR#1,014/2,410 Sec#110/231 |
| Foreign Own. | 2.32% | KR#1,511/2,410 Sec#142/231 |
| Per Share | ||
| EPS | -335 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,013 KRW | KR#2,075/2,410 Sec#174/231 |
Company Info
동사는 1999년 설립된 바이오 벤처기업으로 2011년 코스닥에 상장함. 신약파트는 박테리오파지 플랫폼 기술 기반 itLysin과 IMPA™ 기술분야로 신약개발을 추진하고, DR파트는 PCR 및 qPCR 기반 진단제품 개발·생산으로 수익을 창출함. 플랫폼으로 내성균 치료제, 백신개발, 면역치료제 영역까지 확장하며 'from SUPERBUG to IMMUNE' 개념으로 글로벌 기술을 선도하고 있음. 인트론바이오는 1999년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.